دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Examining the evidence for weight management in individuals with type 2 diabetes
W. Timothy Garvey MD, Guillermo E. Umpierrez MD, Julia P. Dunn MD, Anita Y. M. Kwan MS, Oralee J. Varnado PhD, Manige Konig MD, Joshua A. Levine MD,Â
doi : 10.1111/dom.14764
The obesity epidemic has been linked to the worsening diabetes epidemic. Despite this, weight reduction for individuals with obesity is seen as a secondary, or even tertiary, consideration in the treatment of type 2 diabetes (T2D).
Metformin-induced vitamin B12 deficiency can cause or worsen distal symmetrical, autonomic and cardiac neuropathy in the patient with diabetes
David S. H. Bell MB,Â
doi : 10.1111/dom.14734
Metformin blocks the absorption of vitamin B12 through a mechanism that has not been established but could be because of interference with the calcium-dependent binding of the intrinsic factor vitamin B12 complex to the cubam receptor in the terminal ileum.
Rationale, design and baseline characteristics of the effect of canagliflozin in patients with type 2 diabetes and microalbuminuria in the Japanese population: The CANPIONE study
Satoshi Miyamoto MD, Hiddo J. L. Heerspink PhD, Dick de Zeeuw MD, Masao Toyoda MD, Daisuke Suzuki MD, Takashi Hatanaka MD, Tohru Nakamura MD, Shinji Kamei MD, Satoshi Murao MD, Kazuyuki Hida MD, Shinichiro Ando MD, Hiroaki Akai MD, Yasushi Takahashi MD, Daisuke Koya MD, Munehiro Kitada MD, Hisashi Sugano MD, Tomokazu Nunoue MD, Akihiko Nakamura MD, Motofumi Sasaki MD, Tatsuaki Nakatou MD, Kei Fujimoto MD, Daiji Kawanami MD, Takashi Wada MD, Nobuyuki Miyatake MD, Michihiro Yoshida PhD, Kenichi Shikata MD, the CANPIONE study Investigators ,Â
doi : 10.1111/dom.14731
To evaluate the effect of canagliflozin, a sodium-glucose co-transporter-2 (SGLT2) inhibitor, on albuminuria and the decline of estimated glomerular filtration rate (eGFR) in participants with type 2 diabetes and microalbuminuria.
Impact of the hepatoselective glucokinase activator TTP399 on ketoacidosis during insulin withdrawal in people with type 1 diabetes
Klara R. Klein MD, Schafer C. Boeder MD, Jennifer L. R. Freeman PhD, Imogene Dunn PhD, Chris Dvergsten PhD, Supradeep Madduri BS, Erin R. Giovannetti FNP-C, Carmen Valcarce PhD, John B. Buse MD, Jeremy H. Pettus MD,Â
doi : 10.1111/dom.14697
To determine the effect of TTP399, a hepatoselective glucokinase activator, on the risk of ketoacidosis during insulin withdrawal in individuals with type 1 diabetes (T1D).
Comparative efficacy of novel antidiabetic drugs on cardiovascular and renal outcomes in patients with diabetic kidney disease: A systematic review and network meta-analysis
Hongwei Cao MD, Tao Liu MM, Li Wang MD, Qiuhe Ji MD,Â
doi : 10.1111/dom.14702
To conduct a systematic review and network meta-analysis to determine the comparative effectiveness of sodium-glucose cotransporter-2 (SGLT2) inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dipeptidyl peptidase-4 (DPP-4) inhibitors in patients with diabetic kidney disease (DKD).
Effectiveness of low-carbohydrate diets for long-term weight loss in obese individuals: A meta-analysis of randomized controlled trials
Giovanni Antonio Silverii MD, Claudia Cosentino MD, Federica Santagiuliana RD, Francesco Rotella MD, Federica Benvenuti MD, Edoardo Mannucci MD, Barbara Cresci MD,Â
doi : 10.1111/dom.14709
To assess whether low-carbohydrate (LC) diets are associated with differences in weight loss and well-being in people with obesity, and their cardiovascular and renal safety.
Cardiovascular and renal outcomes of initial combination therapy with glucose-lowering agents versus a stepwise approach in newly diagnosed or treatment-naïve type 2 diabetes: A systematic review and meta-analysis
Samuel Seidu, Abdullah Almaqhawi, Mohammad Abdool, Setor K. Kunutsor, Melanie J. Davies, Kamlesh Khunti,Â
doi : 10.1111/dom.14715
To evaluate the efficacy and safety of the initial combination therapy versus a stepwise approach in newly diagnosed type 2 diabetes (T2D) by conducting a systematic review and meta-analysis of observational cohort studies and randomized controlled trials (RCTs).
Severe iatrogenic hypoglycaemia modulates the fibroblast growth factor protein response
Manjula Nandakumar PhD, Abu Saleh Md Moin PhD, Manjunath Ramanjaneya PhD, Ahmed Al Qaissi, Thozhukat Sathyapalan MD, Stephen L. Atkin MD, Alexandra E. Butler MD,Â
doi : 10.1111/dom.14716
There is evidence that fibroblast growth factor (FGF) levels may be implicated in hypoglycaemia, with FGF19 being a potential contributor to insulin-independent pathways driving postprandial hypoglycaemia following bariatric surgery and basic FGF (FGF2) being elevated following mild hypoglycaemia occurring after the glucose tolerance test. However, their response following severe iatrogenic hypoglycaemia is unknown and therefore this pilot exploratory study was undertaken.
Positive allosteric γ-aminobutyric acid type A receptor modulation prevents lipotoxicity-induced injury in hepatocytes in vitro
Elisabeth Rohbeck MSc, Birgit Hasse PhD, Guido Koopmans PhD, Alejandra Romero PhD, Bengt-Frederik Belgardt PhD, Michael Roden MD, PhD, Prof, Jürgen Eckel PhD, Prof, Tania Romacho PhD,Â
doi : 10.1111/dom.14719
To determine if a novel positive allosteric modulator of the γ-aminobutyric acid type A (GABAA) receptor, the thioacrylamide-derivative HK4, which does not penetrate the blood–brain barrier, protects human hepatocytes against lipotoxicity-induced injury.
The effects of empagliflozin, dietary energy restriction, or both on appetite-regulatory gut peptides in individuals with type 2 diabetes and overweight or obesity: The SEESAW randomized, double-blind, placebo-controlled trial
Jack A. Sargeant PhD, James A. King PhD, Thomas Yates PhD, Emma L. Redman PhD, Danielle H. Bodicoat PhD, Sudesna Chatterjee MD, Charlotte L. Edwardson PhD, Laura J. Gray PhD, Benoit Poulin PhD, Ghazala Waheed MSc, Helen L. Waller PhD, David R. Webb PhD, Scott A. Willis PhD, John P. H. Wilding DM, Kamlesh Khunti PhD, David J. Stensel PhD, Melanie J. Davies MD,Â
doi : 10.1111/dom.14721
To assess the impact of the sodium-glucose co-transporter-2 (SGLT2) inhibitor empagliflozin (25 mg once-daily), dietary energy restriction, or both combined, on circulating appetite-regulatory peptides in people with type 2 diabetes (T2D) and overweight or obesity.
Efficacy and safety benefits of iGlarLixi versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with suboptimally controlled type 2 diabetes on oral agents: The LixiLan-O-AP randomized controlled trial
Wenying Yang MD, Xiaolin Dong MD, Qingju Li MD, Zhifeng Cheng MD, Guoyue Yuan MD, Ming Liu MD, Jianzhong Xiao MD, Shenghong Gu MCM, Elisabeth Niemoeller MD, Lijuan Chen MS, Lin Ping MD, Elisabeth Souhami MD, LixiLan-O-AP trial investigators ,Â
doi : 10.1111/dom.14722
To compare the efficacy and safety of iGlarLixi with insulin glargine 100 units/mL (iGlar) and lixisenatide (Lixi), in Asian Pacific people with suboptimally controlled type 2 diabetes (T2D) on metformin with or without a second oral antihyperglycaemic drug (OAD).
Combined therapy with CD4+CD25highCD127− T regulatory cells and anti-CD20 antibody in recent-onset type 1 diabetes is superior to monotherapy: Randomized phase I/II trial
Maciej ZieliÅ„ski PhD, Magdalena Å»aliÅ„ska MD, Dorota Iwaszkiewicz-GrzeÅ› PhD, Mateusz GliwiÅ„ski MSc, Matylda Hennig MD PhD, Anna JaźwiÅ„ska-CuryÅ‚Å‚o MD, Halla KamiÅ„ska MD PhD, Justyna Sakowska MSc, Anna WoÅ‚oszyn-Durkiewicz MD, RadosÅ‚aw Owczuk MD PhD, Wojciech MÅ‚ynarski MD PhD, PrzemysÅ‚awa Jarosz-Chobot MD PhD, Artur Bossowski MD PhD, Agnieszka Szadkowska MD PhD, Janusz Siebert MD PhD, MaÅ‚gorzata MyÅ›liwiec MD PhD, Natalia Marek-Trzonkowska MD PhD, Piotr Trzonkowski MD PhD,Â
doi : 10.1111/dom.14723
Monotherapy with autologous expanded CD4+CD25highCD127− T regulatory cells (Tregs) or rituximab has been documented to slow disease progression in patients with recent-onset type 1 diabetes mellitus (T1DM). Whether a combined therapy including both drugs would further benefit this patient population is unknown.
A randomized pharmacokinetic and pharmacodynamic trial of two regular human insulins demonstrates bioequivalence in type 1 diabetes and availability of biosimilar insulin may improve access to this medication
Sérgio Vencio MD, Rafael Caiado-Vencio MD, Leonardo Ferreira Caixeta MD, MaÅ‚gorzata Masierek MD, Wojciech Mlynarski MD, Józef Drzewoski MD, Justin M. Gregory MD,Â
doi : 10.1111/dom.14724
To compare the pharmacokinetic (PK) and pharmacodynamic (PD) effects and safety of therapeutic dosages of a regular insulin (experimental drug) produced by Bioton S.A. (Warsaw, Poland) versus Humulin® R, a regular insulin (reference drug) produced by Eli Lilly (Indianapolis, Indiana).
Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension
John P. H. Wilding D.M, Rachel L. Batterham MBBS, Melanie Davies M.D, Luc F. Van Gaal M.D, Kristian Kandler M.D, Katerina Konakli PhD, Ildiko Lingvay M.D, Barbara M. McGowan M.D, Tugce Kalayci Oral MD, Julio Rosenstock M.D, Thomas A. Wadden Ph.D, Sean Wharton M.D, Koutaro Yokote M.D, Robert F. Kushner M.D, STEP 1 Study Group ,Â
doi : 10.1111/dom.14725
To explore changes in body weight and cardiometabolic risk factors after treatment withdrawal in the STEP 1 trial extension.
Therapeutic indications and metabolic effects of metreleptin in patients with lipodystrophy syndromes: Real-life experience from a national reference network
Héléna Mosbah MD, Marie-Christine Vantyghem MD, Estelle Nobécourt MD, Fabrizio Andreelli MD, Francoise Archambeaud MD, Elise Bismuth MD, Claire Briet MD, Maryse Cartigny MD, Benjamin Chevalier MD, Bruno Donadille MD, Anne Daguenel PharmD, Mathilde Fichet MD, Jean-François Gautier MD, Sonja Janmaat PhD, Isabelle Jéru PharmD, Carole Legagneur MD, Lysiane Leguier MD, Julie Maitre MD, Elise Mongeois MD, Christine Poitou MD, Eric Renard MD, Yves Reznik MD, Anne Spiteri MD, Florence Travert MD, Bruno Vergès MD, Jamila Zammouri MD, Corinne Vigouroux MD, Camille Vatier MD,Â
doi : 10.1111/dom.14726
To describe baseline characteristics and follow-up data in patients with lipodystrophy syndromes treated with metreleptin in a national reference network, in a real-life setting.
Effects of dapagliflozin on volume status and systemic haemodynamics in patients with chronic kidney disease without diabetes: Results from DAPASALT and DIAMOND
Taha Sen PharmD, Rosalie Scholtes MD, Peter J. Greasley PhD, David Z. I. Cherney MD PhD, Claire C. J. Dekkers MD PhD, Marc Vervloet MD PhD, Alexander H. J. Danser PharmD PhD, Sean J. Barbour MD PhD, Cecilia Karlsson MD PhD, Ann Hammarstedt PhD, Qiang Li PhD, Gozewijn D. Laverman MD PhD, Petter Bjornstad MD PhD, Daniel H. van Raalte MD PhD, Hiddo J. L. Heerspink PharmD PhD,Â
doi : 10.1111/dom.14729
To assess the effect of sodium-glucose cotransporter-2 inhibitor dapagliflozin on natriuresis, blood pressure (BP) and volume status in patients with chronic kidney disease (CKD) without diabetes.
Combination therapy with exenatide decreases the dapagliflozin-induced changes in brain responses to anticipation and consumption of palatable food in patients with type 2 diabetes: A randomized controlled trial
Charlotte C. van Ruiten MD, Dick J. Veltman MD, PhD, Madelief Wijdeveld MSc, Jennifer S ten Kulve MD, PhD, Mark H. H. Kramer MD, PhD, Max Nieuwdorp MD, PhD, Richard G. IJzerman MD, PhD,Â
doi : 10.1111/dom.14732
Sodium-glucose cotransporter-2 inhibitors induce less weight loss than expected. This may be explained by sodium-glucose cotransporter-2 inhibitor-induced alterations in central reward- and satiety circuits, leading to increased appetite and food intake.
Non-inferiority and clinical superiority of glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors: Systematic analysis of cardiorenal outcome trials in type 2 diabetes
Francesco Zaccardi PhD, David E. Kloecker MPhil, Kamlesh Khunti PhD, Melanie J. Davies MD,Â
doi : 10.1111/dom.14735
Most trials leading to the approval of glucagon-like peptide receptor agonists (GLP-1RAs) and sodium-glucose co-transporter-2 inhibitors (SGLT2is) were primarily designed to confirm their non-inferiority to placebo (commonly using an upper 95% confidence limit threshold of 1.3) and, if confirmed, superiority (threshold 1): this asymmetry of margins (1 vs. 1.3) favours the active intervention. We aimed to quantify the probability of clinical superiority of the active treatment by applying the same threshold used to claim non-inferiority.
The time-varying cardiovascular benefits of glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes mellitus: Evidence from large multinational trials
Salil V. Deo MD, Shayan Marsia MBBS, David A. McAllister MD, Yakov Elgudin MD, Naveed Sattar MD, Jill P. Pell MD,Â
doi : 10.1111/dom.14738
To evaluate the time-varying cardio-protective effect of glucagon-like peptide-1 receptor agonists (GLP-1RAs) using pooled data from eight contemporary cardiovascular outcome trials using the difference in the restricted mean survival time (�RMST) as the effect estimate.
Real-world outcomes of addition of insulin glargine 300 U/mL (Gla-300) to glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy in people with type 2 diabetes: The DELIVER-G study
Timothy S. Bailey, Jasvinder Gill, Merwyn Jones S., Laxmi Shenoy, Charlie Nicholls, Jukka Westerbacka,Â
doi : 10.1111/dom.14739
To provide real-world data on the addition of basal insulin (BI) in people with type 2 diabetes mellitus (PWD2) suboptimally controlled with glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy. However, real-world data on the addition of BI to GLP-1RA therapy are limited.
Comparative cardiovascular effectiveness of glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: A population-based cohort study
Yaa-Hui Dong PhD, Chia-Hsuin Chang MD, Jou-Wei Lin MD, Wei-Shun Yang MD, Li-Chiu Wu MS, Sengwee Toh ScD,Â
doi : 10.1111/dom.14741
To examine the comparative effectiveness of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 (SGLT2) inhibitors for select cardiovascular outcomes and to examine whether the relative risks varied across different patient subgroups in patients with type 2 diabetes.
The effect of liraglutide on cardiac autonomic function in type 2 diabetes: A prespecified secondary analysis from the LIRAFLAME randomized, double-blinded, placebo-controlled trial
Suvanjaa Sivalingam MD, Emilie Hein Zobel MD, Christian S. Hansen PhD, Rasmus S. Ripa DMSc, Bernt J. von Scholten DMSc, Viktor Rotbain Curovic MD, Andreas Kjaer DMSc, Jacob K. Jensen MD, Tine W. Hansen PhD, Peter Rossing DMSc,Â
doi : 10.1111/dom.14717
Comparison of the injection-site experience of semaglutide in a single-dose and a multidose pen-injector
Søren Snitker MD, PhD, Andreas Andersen PhD, Pernille Skøtt Lindskov MSc, Sjoerd van Marle MD, Birgitte Fischer Sode MD, PhD, Thomas Sparre MD, PhD,Â
doi : 10.1111/dom.14718
Association between treatment effect on C-peptide preservation and HbA1c in meta-analysis of glutamic acid decarboxylase (GAD)-alum immunotherapy in recent-onset type 1 diabetes
Christoph Nowak MD-PhD, Ulf Hannelius PhD, Johnny Ludvigsson MD-PhD,Â
doi : 10.1111/dom.14720
Cholecystectomy is associated with dysglycaemia: Cross-sectional and prospective analyses
Miaomiao Sang MD, Cong Xie PhD, Shanhu Qiu MD, Xuyi Wang PhD, Michael Horowitz PhD, Karen L. Jones PhD, Christopher K. Rayner PhD, Zilin Sun PhD, Tongzhi Wu PhD,Â
doi : 10.1111/dom.14730
Cholecystectomy has been reported to be associated with increased risk of diabetes in cross-sectional studies. In the current study, we performed both cross-sectional and prospective analyses to examine the association between cholecystectomy and dysglycaemia in Chinese community-dwelling adults.
Eight weeks of empagliflozin does not affect pancreatic fat content and insulin secretion in people with prediabetes
Julia Hummel, Jürgen Machann, Corinna Dannecker, Stephanie Kullmann, Andreas L. Birkenfeld, Hans-Ulrich Häring, Andreas Peter, Andreas Fritsche, Robert Wagner, Martin Heni,Â
doi : 10.1111/dom.14733
Smartwatch gesture-based meal reminders improve glycaemic control
John P. Corbett PhD, Liana Hsu BS, Sue A. Brown MD, Laura Kollar RN, Katelijn Vleugels PhD, Bruce Buckingham MD, Marc D. Breton PhD, Rayhan A. Lal MD,Â
doi : 10.1111/dom.14737
Reducing hyperglucagonaemia in type 2 diabetes using low-dose glibenclamide: Results of the LEGEND-A pilot study
Ioannis I. Spiliotis, Rod Chalk, Stephen Gough, Patrik Rorsman,Â
doi : 10.1111/dom.14740
Effect of glucagon-like peptide-1 receptor agonists on cardiovascular events in overweight or obese adults without diabetes: A meta-analysis of placebo-controlled randomized trials
Ana Rita Leite, António Angélico-Gonçalves, Francisco Vasques-Nóvoa, Marta Borges-Canha, Adelino Leite-Moreira, João Sérgio Neves, João Pedro Ferreira,Â
doi : 10.1111/dom.14707
Our aim was to study the effect of glucagon-like peptide-1 receptor agonists (GLP-1 RA) on the risk of any cardiovascular event in adults with overweight or obesity and without diabetes. We conducted a random-effects meta-analysis of placebo-controlled randomized controlled trials.
Letter of reply to the letter by Ryan
João Pedro Ferreira MD, Ana Leite MD, António Gonçalves MD, Marta Canha MD, João Sérgio Neves MD,Â
doi : 10.1111/dom.14743
